(Reuters) -Intellia Therapeutics said on Monday it has temporarily stopped dosing and screening patients in two late-stage studies of its one-time gene-editing treatment for a heart condition after a patient experienced a serious liver problem.

(Reporting by Padmanabhan Ananthan in Bengaluru; Editing by Shailesh Kuber)

See Full Page